.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE01_Cetuximab.Cetuximab

Information

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), used in the treatment of certain types of cancer such as metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It is approved and in clinical use.

Pharmacokinetics

Population pharmacokinetic parameters in adult patients with advanced solid tumors receiving intravenous infusion.

References

1. Shibata, K, et al., & Kawakami, J (2021). Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. Cancer chemotherapy and pharmacology 87(4) 555–565. DOI:10.1007/s00280-020-04228-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33462734

2. Xu, J, et al., & Ding, Y (2025). A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux. Advances in therapy 42(6) 2797–2807. DOI:10.1007/s12325-025-03193-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40232626

3. Guo, Y, et al., & Shi, Y (2015). Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. Head & neck 37(8) 1081–1087. DOI:10.1002/hed.23707 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24710768

Revisions

• 06/2025 initial generated model